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Abstract
Background. Iron deficiency is a common cause of anae-
mia and hyporesponsiveness to erythropoiesis-stimulating
agents (ESAs) in non-dialysis-dependent chronic kidney
disease(ND-CKD)patients.Currentintravenousironagents
cannot be administered in a single high dose because of
adverse effects. Ferric carboxymaltose, a non-dextran par-
enteral iron preparation, can be rapidly administered in
high doses.
Methods. This open-label trial randomized 255 subjects
with glomerular filtration rates ≤45 mL/min/1.73 m
2,
haemoglobin ≤11 g/dL, transferrin saturation ≤25%,
ferritin ≤300 ng/mL, and stable ESA dose to either intra-
venous ferric carboxymaltose 1000 mg over 15 min (with
up to two additional doses of 500 mg at 2-week intervals)
or oral ferrous sulphate 325 mg thrice daily for a total of
195 mg elemental iron daily for 56 days.
Results. In the modified intent-to-treat population, the
proportion of subjects achieving a haemoglobin increase
≥1 g/dL at any time was 60.4% with ferric carboxymaltose
and 34.7% with oral iron (P < 0.001). At Day 42, mean
increase in haemoglobin was 0.95 ± 1.12 vs 0.50 ±
1.23 g/dL (P = 0.005), mean increase in ferritin was 432 ±
189ng/mLvs18±45ng/mL(P<0.001)andmean increase
in transferrin saturation was 13.6 ± 11.9% vs 6.1 ± 8.1%
(P < 0.001). Treatment-related adverse events were signifi-
cantly fewer with ferric carboxymaltose than with oral iron
(2.7% and 26.2%, respectively; P < 0.0001).
Conclusions. We conclude that 1000 mg ferric carboxy-
maltose can be rapidly administered, is more effective
and is better tolerated than oral iron for treatment of iron
deficiency in ND-CKD patients.
Keywords: anaemia; CKD; ferritin; intravenous iron; transferrin
saturation
Introduction
Iron deficiency is frequently encountered in anaemic non-
dialysis-dependent chronic kidney disease (ND-CKD)
patients. Indeed, the prevalence of low iron indices such
as transferrin saturation (TSAT) levels <20% and ferritin
levels <100 ng/mL is 20–70%, depending on CKD stage
[1–3]. Moreover, iron deficiency is the most common
cause of hyporesponsiveness to erythropoiesis-stimulating
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improvesiron indices andhaemoglobin (Hb) concentration,
andreduces therequired ESAdose[5–11].Thus,correction
of anaemia in CKD patients requires careful balance of the
ESA and iron.
The current National KidneyFoundation KidneyDisease
Outcomes Quality Initiative guidelines recommend either
oral or intravenous (IV) iron in iron-deficient, anaemic
ND-CKD patients [12]. Unfortunately, administration of
oral iron is limited by poor gastrointestinal absorption and
high rate of adverse events [13–16]. Over 30% of patients
may experience adverse events that result in dose reduction
and/ornon-adherencetotreatment[15].Alternatively,avail-
able IViron formulations are limited by the maximum dose
that can be given in a singlevisit, although higher non-FDA
approved doses have been given [17–19]. The administra-
tion of the typical 1000-mg course would require at least
10dosesof irondextran,8dosesofferricgluconate,5doses
of ironsucroseor2dosesofferumoxytol,whichcanbeboth
inconvenient and costly for patients and healthcare provi-
ders. Thus, there is a need for an IV iron agent that can be
safely administered in large single doses, which require less
frequent clinic visits and fewer venipunctures.
Ferric carboxymaltose (FCM, manufactured in the USA
by American Regent, Shirley, NY, USA under licence from
Vifor Pharma Ltd, Switzerland) is a stable type I poly-
nuclear iron (III)–hydroxide carbohydrate complex. It is
a novel, non-dextran iron preparation that was developed
for rapid IVadministration in high doses for the treatment
of iron deficiency anaemia [20–22]. The FCM complex
has a nearly neutral pH (5.0–7.0), physiologic osmolarity,
and no cross-reactivity with dextran. It is generally less re-
active than iron gluconate and iron sucrose, producing
s l o wa n dc o n t r o l l e dd e l i v e r yo fi r o ni n t ot a r g e tt i s s u e s
[20–22]. As a result, rapid infusion of up to 1000 mg of
FCM over 15 min is well tolerated [20–22].
This phase 3, open-label, randomized, controlled, multi-
centre trial was designed to compare the efficacy and
safety of large doses of FCM, given intravenously over
15 min, with oral ferrous sulphate to ND-CKD patients.
Materials and methods
This phase 3, open-label, randomized, controlled, multicentre trial was
conducted between May 2005 and February 2007 in 47 centres. The study
protocol and the informed consent form were approved by the institutional
review boards of each participating centre. The trial complied with the
Declaration of Helsinki.
Subjects ≥12 years of age with estimated glomerular filtration rate
(GFR) ≤45 mL/min/1.73 m
2,H bl e v e l≤11 g/dL, TSAT ≤25% and fer-
ritin ≤300 ng/mL were enrolled. Those taking ESA had to be on fixed
doses for ≥8 weeks prior to study enrolment. Exclusion criteria included a
history of gastrointestinal intolerance to oral iron, IV iron within 12 weeks
prior to the study, significant blood loss or blood transfusion within the
last 12 weeks, active infection, concomitant severe liver or cardiovascular
diseases, severe psychiatric disorders, pregnant or lactating women,
known hepatitis B or hepatitis C infection, HIV, anticipated dialysis or
renal transplant in the next 3 months, chronic alcohol or drug abuse with-
in the past 6 months, an investigational drug in the previous 30 days, or
any condition which, in the opinion of the investigator, made participation
unacceptable.
At randomization, subjects were stratified by severity of CKD based
on GFR, baseline Hb and use of ESA. The starting ESA dose was main-
tained for the duration of the study unless safety concerns dictated a
change.
Study design
Subjects who provided informed consent entered the 2–9-week screening
phase (Figure 1), during which those who met the study criteria under-
went history and clinical evaluation, and discontinued any non-study oral
iron therapy. Subjects were randomized into the treatment phase at Week
0 by a centralized interactive voice-response system. Initial randomization
was in a 2:1 ratio of FCM to oral iron, but because of slow enrolment, the
protocol was amended during the trial to a 1:1 ratio. A total of 80 FCM
and 40 oral iron subjects were already enrolled at the time of the change in
randomization ratio. The remaining 140 were randomized in a 1:1 ratio.
Study subjects were randomized into two arms. The first arm received
up to three IV infusions of FCM (n = 147). The second arm received oral
ferrous sulphate 325 mg orally 1 h before meals three times daily (195 mg
elemental iron) for 56 days (Figure 1). FCM was infused over 15 min at a
maximum dose of 1000 mg (15 mg/kg) diluted in 250 mL normal saline.
If TSAT remained <30% and ferritin remained <500 ng/mL, two add-
itional doses of FCM, each at a maximum dose of 500 mg in 100 mL
normal saline, were infused on approximately Day 17 and/or Day 31.
Subjects were evaluated clinically prior to drug administration, immedi-
ately after, and 30 and 60 min after FCM infusion.
Laboratory tests were obtained at baseline and all follow-up visits at
the end of Week 2, 4, 6 and 8 or early termination visit (End of Study).
Samples were analysed by three central laboratories (ICON Laboratories,
Farmingdale, NY, USA; SydPath Clinical Trials, Sydney, NSW, Australia;
and ALab Clinical Trials Centre, Queen Mary Hospital, Hong Kong,
China). All females were tested for pregnancy at baseline and at the
end of study.
Statistical analyses
The primary efficacy end point of this study was the percentage of sub-
jects achieving an increase in Hb of ≥1.0 g/dL at any study point between
baseline and End of Study or introduction or dose increase of ESA, blood
transfusion, or use of iron outside of protocol.
The major predefined secondary efficacy end points included percent
of subjects achieving a clinical response (defined as increase in Hb ≥1.0
g/dL and an increase in ferritin ≥160 ng/mL); mean change in Hb from
baseline to end of Week 6 (Day 42) and end of Week 8 (Day 56)/End of
Study; percentage of subjects achieving an increase from baseline in Hb
of ≥1.0 g/dL on or before the end of Week 6; and mean change from
baseline to highest Hb.
The safety population included all subjects who took at least one dose
of study medication. Adverse events were reported from the day of initial
treatment to the completion of the study (end of Week 8) or 21 days after
the last treatment, whichever was later.
The efficacy analyses were based on the modified intent-to-treat
(mITT) population, which included all subjects who received at least
one dose of study medication, had results of at least one post-baseline
Hb level, had stable ESA dose for at least 8 weeks before randomization
and had a GFR ≤45 mL/min/1.73 m
2. Sample size calculation was based
on the assumption that the proportion of subjects with an increase in Hb
of ≥1.0 g/dL anytime between baseline and end of study or time of inter-
vention would be 45% for FCM and 25% for oral iron.
Treatment differences for proportions were assessed with Fisher’s exact
test. The t-test was used for mean changes. The effect of baseline char-
acteristics on the primary efficacy end point was examined by means of
logistic regression. Missing data for the summary of percentage of sub-
jects achieving the primary efficacy end point across weeks were esti-
mated with the last observation carried forward. Otherwise, missing
data were not imputed.
Results
Of 637 ND-CKD patients screened, 255 were randomly as-
signed to the study: 152 to FCM and 103 to oral ferrous
sulphate. Five subjects in the FCM group and none in the
1600 W.Y. Qunibi et al.Fig. 1. Patient disposition.
Table 1. Baseline characteristics of subjects who received ≥1 dose of the study drug (safety population)
FCM (n = 147) Oral iron (n = 103) P-value
Age (years) 65.4 ± 12.6 66.8 ± 13.5 0.39
a
Sex (% female) 63.9 70.9 0.28
b
Race (%) 0.16
b
Caucasian 49.0 58.3
African American 27.9 26.2
Hispanic 15.6 9.7
Asian 6.1 5.8
Other 1.4 0.0
Weight (kg) 84.6 ± 23.0 89.5 ± 27.2 0.12
a
Height (cm) 163.8 ± 11.7 164.3 ± 8.6 0.73
a
CKD degree (%) 0.67
b
30.1–45.0 mL/min/1.73 m
2 32.7 32.0
15.1–30.0 mL/min/1.73 m
2 53.1 49.5
≤15.0 mL/min/1.73 m
2 14.3 18.4
Hb (g/dL) 10.1 ± 0.74 10.0 ± 0.86 0.38
a
Hb category (%) 0.70
b
Hb ≤9.0 g/dL 10.2 13.6
Hb 9.1–10.0 g/dL 26.5 26.2
Hb 10.1–11.0 g/dL 63.3 60.2
Ferritin (ng/mL) 111.8 ± 85.1 104.8 ± 75.1 0.50
a
TSAT (%) 15.4 ± 5.5 15.8 ± 5.6 0.59
a
Previous iron therapy (%) 44.2 56.3 0.07
b
History of sensitivity to IV iron (%) 2.0 1.9 1.00
b
ESA use at baseline (%) 23.8 25.2 0.88
b
Values are expressed as mean ± standard deviation or percentage.
CKD, chronic kidney disease; ESA, erythropoiesis-stimulating agent; FCM, ferric carboxymaltose; Hb, haemoglobin; IV , intravenous; TSAT, transferrin
saturation.
at-test.
bFisher’s exact test.
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dose, leaving 147 subjects in the FCM group and 103 in
the oral iron group (Figure 1). In the FCM group, 91.2%
of subjects (n = 134) completed the study vs 81.6% (n =
84) in the oral iron group. Three subjects who lacked post-
baseline Hb levels were removed from the mITT analysis:
one in the FCM group and two in the oral iron group; two
subjects in the FCM group were removed because of an
unstable dose of ESA before randomization. Thus, a total
of 245 subjects were included in the mITTanalysis: 144 in
the FCM group and 101 in the oral iron group (Figure 1).
Mean subject age was 65.4 years in the FCM group and
66.8 years in the oral iron group (P = 0.39). There were no
significant differences between the two groups with re-
spect to demographic or baseline anaemia-related labora-
tory characteristics (Table 1). The proportion of subjects
with baseline Hb ≤9.0 g/dL was 10.2% in the FCM group
and 13.6% in the oral iron group. The majority of subjects
in both treatment groups did not receive an ESA. The per-
centage of subjects in the mITT safety population who had
received previous iron therapy was 44.2% in the FCM
group vs 56.3% in the oral iron group (P = 0.07).
The mean cumulative dose of iron for the mITT popu-
lation was 1218 ± 333 mg in the FCM group vs 9322 ±
2638 mg in the oral iron group. Fifty-eight percent of the
FCM subjects received only one dose.
Efficacy
The proportion of subjects who achieved the primary effi-
cacy end point of an increase in Hb of ≥1.0 g/dL at any
study point between the baseline and End of Study visits
was almost twice as great with FCM as with oral iron
(60.4% vs 34.7%, P < 0.001) (Figure 2). Greater propor-
tions of FCM subjects compared with oral iron subjects
Fig. 2. Percent of subjects (mITT population) achieving Hb ≥1 g/dL at any study time point (last observation carried forward). Hb, haemoglobin;
mITT, modified intention-to-treat.
Table 2. Summary of subjects who achieved the primary end point of an
increase in Hb ≥1.0 g/dL anytime during the study by subgroup (mITT
population)
FCM
n/N (%)
Oral iron
n/N (%) P-value
Baseline Hb
Hb ≤9.0 g/dL 9/14 (64.3) 5/14 (35.7) 0.257
Hb 9.1–10.0 g/dL 28/38 (73.7) 14/27 (51.9) 0.113
Hb 10.1–11.0 g/dL 50/92 (54.3) 16/60 (26.7) <0.001
CKD degree
30.1–45.0mL/min/1.73m
2 33/48 (68.8) 5/18 (27.8) 0.192
15.1–30.0 mL/min/
1.73 m
2
43/75 (57.3) 18/51 (35.3) 0.019
≤15.0 mL/min/1.73 m
2 11/21 (52.4) 5/18 (37.5) 0.011
Baseline ferritin
<100 ng/mL 56/78 (71.8) 21/51 (41.2) <0.001
≥100 ng/mL 31/66 (47.0) 14/50 (28.0) 0.054
Baseline TSAT
<15% 47/61 (77.0) 20/41 (48.8) 0.005
15–<20% 24/50 (48.0) 8/35 (22.9) 0.024
20–25% 16/33 (48.5) 7/25 (28.0) 0.175
ESA use at baseline
No 59/111 (53.2) 23/77 (29.9) 0.002
Yes 28/33 (84.8) 12/24 (50.0) 0.008
Race
Caucasian 47/71 (66.2) 22/59 (37.3) 0.001
Non-Caucasian 40/73 (54.8) 13/42 (31.0) 0.019
Gender
Female 54/91 (59.3) 24/71 (33.8) 0.002
Male 33/53 (62.3) 11/30 (36.7) 0.039
Age
<65 years 45/64 (70.3) 16/42 (38.1) 0.001
≥65 years 42/80 (52.5) 19/59 (32.2) 0.024
CKD, chronic kidney disease; ESA, erythropoiesis-stimulating agent;
FCM, ferric carboxymaltose; Hb, haemoglobin; mITT, modified
intention-to-treat; n/N number of subjects with response/number of sub-
jects in group; TSAT, transferrin saturation.
1602 W.Y. Qunibi et al.achievedanincreaseinHb≥1.0g/dLonorbeforeeachvisit
(Figure 2). The difference was significant regardless of age,
gender, race, or ESA use at baseline. It was also significant
in subgroups with baseline ferritin <100 ng/mL, baseline
Hb 10.1–11.0 g/dL and GFR >15.0 mL/min/1.73 m
2
(Table 2). Logistic regression analyses indicated that only
higher baseline TSAT values were associated with de-
creased odds of achieving an increase in Hb ≥1.0 g/dL dur-
ing the study. The superiority of FCM over oral iron was
unaffected by baseline TSAT.
In the mITT population, a statistically significant differ-
ence favouring FCM was observed for each of the major
secondary efficacy end points. Haemoglobin concentra-
tions increased from baseline in both groups but were
higher at every study time point during FCM treatment
(Figure 3A). The mean change to highest Hb level was sig-
Fig. 3. Mean (SE) for (A)h a e m o g l o b i n( g / d L ) ,( B) ferritin (ng/mL) and (C) TSAT (%) values by treatment group over time. FCM, ferric
carboxymaltose; TSAT, transferrin saturation. *Significantly higher compared with baseline value in the FCM group. P-values are from unpaired
two-sample t-tests, assuming equal variances for differences in change from baseline, and are for differences between the FCM and oral iron
groups at various study points.
Ferric carboxymaltose in iron deficiency anaemia of CKD 1603nificantly greater throughout the study in the FCM group
(1.31 ± 1.11 vs 0.83 ± 1.18 g/dL, P = 0.001), as was the
mean increase in Hb by the end of Week 8 (1.05 ± 1.10 vs
0.70 ± 1.25 g/dL; P = 0.034). For subjects receiving <1 g of
FCM,Hbincreasedfrombaselineof10.26±0.66to10.97±
1.03g/dLatDay56(P<0.001).Forsubjects receiving>1g
of FCM, Hb increased from baseline of 10.0 ± 0.78 to
11.46 ± 1.2 g/dL at Day 56 (P < 0.001). Other Hb-related
parameters that were significantly higher in the FCM group
were increase from baseline in mean haematocrit, mean
corpuscular volume, mean corpuscular Hb, mean reticulo-
cyte haemoglobin and mean red cell distribution width.
Significant differences favouring FCM were observed
for each of the remaining major secondary efficacy end
points (proportion of subjects with ferritin change ≥160
ng/mL; proportion with Hb change ≥1.0 g/dL on or before
end of Week 4, 6 and 8; and mean Hb change from baseline
to end of Week 4, 6 and 8/End of Study).
The mean increase in serum ferritin values from baseline
was significantly greater throughout the treatment period
in the FCM group than in the oral iron group. The differ-
ence was 620.8 ± 255.2 vs 7.7 ± 34.4 ng/mL at Week 2
and 358.8 ± 178.4 vs 25.8 ± 49.4 ng/mL at Week 8/End
of Study in the mITT population (P < 0.001) (Figure 3B).
The mean increase to the highest ferritin during the study
was also greater with FCM (673.8 ± 232.1 vs 38.1 ±
49.6 ng/mL; P < 0.001) (Figure 3B). The increase from
baseline in mean serum ferritin declined slowly from Week
2 to Week 8 in the FCM group. The mean TSAT level also
increased significantly more in the FCM-treated subjects at
end of Week 8 compared with the oral iron group (12.1 ±
8.8% vs 7.0 ± 10.3%; P < 0.001) (Figure 3C), and greater
increases from baseline to the highest TSATwere observed
in the FCM-treated subjects (19.2% ± 11.5% vs 11.3% ±
12.7%; P < 0.001). Similarly, the mean increase from base-
line in reticulocyte Hb concentration values at end of Week
8 was significantly higher in the FCM group compared
with the oral iron group. The increase from baseline to
the highest reticulocyte Hb content was also higher in the
FCM group (2.46 ± 2.36 vs 1.39 ± 1.98 pg/cell; P < 0.001).
Adherence to therapy during the study was excellent.
The proportion of subjects who used at least 67% of the
study drug was 97.9% in the FCM treatment group and
82.2% in the oral iron group, and the mean study drug
usage based on actual days on study was >95% for both
treatments.
Safety
The most commonly experienced adverse events in the
FCM group were peripheral oedema (6.1%), hyperkalae-
mia (4.1%), urinary tract infection (3.4%), hypotension
(3.4%), bronchitis, headache, and infusion site reaction
(2.0% each) (Table 3). The corresponding rates in the oral
iron were: peripheral oedema (1.9%), hyperkalaemia
(1.0%), urinary tract infection (1.0%), hypotension
(0.0%), headache (1.9%), bronchitis and infusion site reac-
tion (0.0% each). In the FCM treatment group, four prur-
itus/skin rash and five hypotensive events occurred. Only
one of these events, skin rash, was determined to be drug-
related and was rated by the investigator as mild. Each of
the hypotensive episodes was determined by the investiga-
tor to be mild or moderate in severity and not related to the
study drug, and occurred 2–7 weeks after FCM dosing.
The most commonly experienced adverse events in the oral
iron group were constipation (17.5%), nausea (4.9%), diar-
rhoea, upper respiratory tract infection (3.9% each), disco-
loured faeces, and gastrointestinal haemorrhage (2.9%
each) (Table 3). Serious adverse events were recorded in
13 (8.8%) subjects in the FCM group, including two sub-
jects who died, and 10 (9.7%) in the oral iron group. One
subject who died was an 85-year-old man who had a
history of advanced prostate cancer and bladder outlet
obstruction, and experienced severe sepsis 33 days fol-
Table 3. Adverse events experienced by ≥2% of subjects in either treatment group (safety population)
MedDRA SOC-preferred term, n (%) FCM (n = 147) Oral iron (n = 103) P-value
≥1 adverse event 64 (43.5) 61 (59.2) 0.02
Gastrointestinal disorders 12 (8.2) 40 (38.8)
Constipation 2 (1.4) 18 (17.5) <0.001
Diarrhoea 2 (1.4) 4 (3.9) 0.23
Faeces discoloured 0 (0.0) 3 (2.9) 0.07
Gastrointestinal haemorrhage 0 (0.0) 3 (2.9) 0.07
Nausea 2 (1.4) 5 (4.9) 0.13
General disorders and administration site conditions 18 (12.2) 6 (5.8)
Infusion site reactions 3 (2.0) 0 0.27
Oedema peripheral 9 (6.1) 2 (1.9) 0.13
Infections and infestations 20 (13.6) 8 (7.8)
Bronchitis 3 (2.0) 0 0.27
Upper respiratory tract infection 2 (1.4) 4 (3.9) 0.23
Urinary tract infection 5 (3.4) 1 (1.0) 0.41
Metabolism and nutrition disorders 10 (6.8) 3 (2.9)
Hyperkalaemia 6 (4.1) 1 (1.0) 0.25
Nervous system disorders 6 (4.1) 7 (6.8)
Headache 3 (2.0) 2 (1.9) 1.00
Vascular disorders 9 (6.1) 2 (1.9)
Hypotension 3 (2.0) 0 0.08
FCM, ferric carboxymaltose; MedDRA, Medical Dictionary for Regulatory Activities; SOC, System Organ Class.
1604 W.Y. Qunibi et al.lowing his last and only dose of FCM. The other was a
76-year-old man who died as a result of multiple traumas
following a motor vehicle accident. A summary of the sub-
jects who experienced serious adverse events during the
study is presented in Supplementary Table 1. Five
(3.4%) subjects in the FCM group and seven (6.8%) sub-
jects in the oral iron group were prematurely discontinued
from the study drug due to the occurrence of adverse
events. All five of the subjects in the FCM group experi-
enced adverse events that were considered to have no rela-
tionship with the study drug by the investigator. Three of
the seven oral iron subjects who prematurely discontinued
the study drug experienced gastrointestinal symptoms that
were determined to be probably related to the study drug
by the investigator.
The proportion of subjects who experienced at least one
possibly drug-related adverse event was significantly lower
in the FCM group compared with the oral iron group:
2.7% in the FCM group and 26.2% in the oral iron group
(P = 0.0001) (Table 4). No adverse events that were con-
sidered to be drug-related were experienced by more than
one subject in the FCM group. In contrast, events experi-
enced by more than one subject in the oral iron group were
constipation, discoloured faeces, upper abdominal pain,
diarrhoea and nausea. Only one subject in the oral iron
group and none in the FCM group experienced severe ad-
verse events that the investigator considered to be study
drug-related. That subject had severe upper abdominal
pain and severe diarrhoea on study Day 1 and was discon-
tinued from the study.
Asignificantlygreaterbut notclinicallyrelevant increase
in gamma glutamyl transferase (GGT) from baseline to end
of Week 8 was observed in the FCM group compared with
the oral iron group (9.1 vs 0.6 IU/L). However, therewas no
relationship between the FCM dose and the changes in
GGT.
Four (3.8%) subjects in the FCM group had low serum
phosphorus levelsduring the study, but none in the oral iron
group. The low values were transient and did not result in
any clinical adverse event. The lowest serum phosphorus
level during the study was 1.7 mg/dL.
Discussion
Treatment of iron deficiency in ND-CKD patients can be
challenging. Oral iron is associated with significant adverse
events and high degree of non-compliance [13–16,23,24].
Unfortunately, currently available IV iron agents have their
own limitations and have not been consistently shown to be
superior to oral iron in randomized controlled trials [6,14–
16,24,25]. A few studies suggest that oral iron may be as
effective as IV iron [15,24]; however, a greater number of
studies show that IV iron is more effective in increasing
Hb levels and in addition replenishing iron stores [14,25].
This randomized multicentre study in ND-CKD patients
showed that FCM can overcome many of these challenges
as it can be rapidly administered in 1000-mg IV dose in a
single clinic visit. Moreover, the study showed that FCM is
significantly more effective in treating iron deficiency an-
aemia than daily administration of oral ferrous sulphate
over an 8-week treatment period. The superior efficacy
of FCM compared with oral iron in increasing Hb level,
replenishing iron stores and improving the availability of
iron for erythropoiesis was clearly demonstrated. Subjects
in the FCM group were almost twice as likely as those in
the oral iron group to achieve the primary end point of an
increase in Hb ≥1.0 g/dL. This was true regardless of
whether the subjects were receiving ESA therapy at base-
line and regardless of their baseline ferritin level. Similarly,
achievement of other anaemia-related efficacy end points,
such as mean increase in Hb, haematocrit and reticulocyte
Hb content, was also greater in the FCM group. Also,
FCM was more effective than oral iron in increasing body
iron supply for erythropoiesis. The mean increase in fer-
ritin levels indicated greater repletion of body iron stores
with FCM than with oral iron. Similarly, the mean level of
TSAT, another indicator of iron supply for erythropoiesis,
Table 4. Possibly or probably drug-related adverse events experienced by ≥1 subject in either treatment group
MedDRA SOC-preferred term, n (%) FCM (n = 147) Oral iron (n = 103) P-value
≥1 adverse event 4 (2.7) 27 (26.2) <0.0001
Gastrointestinal disorders 1 (0.7) 27 (26.2) <0.0001
Abdominal distension 0 1 (1.0) 0.41
Abdominal pain (upper) 0 2 (1.9) 0.17
Constipation 0 17 (16.5) <0.0001
Diarrhoea 1 (0.7) 2 (1.9) 0.57
Eructation 0 1 (1.0) 0.41
Faeces discoloured 0 3 (2.9) 0.07
Flatulence 0 1 (1.0) 0.41
Frequent bowel movements 0 1 (1.0) 0.41
Nausea 0 2 (1.9) 0.17
Vomiting 0 1 (1.0) 0.41
General disorders and administration site conditions 1 (0.7) 0 1.00
Rigors 1 (0.7) 0 1.00
Skin and subcutaneous tissue disorders 2 (1.4) 0 0.51
Rash 1 (0.7) 0 1.00
Skin discolouration 1 (0.7) 0 1.00
FCM, ferric carboxymaltose; MedDRA, Medical Dictionary for Regulatory Activities; SOC, System Organ Class.
Ferric carboxymaltose in iron deficiency anaemia of CKD 1605increased significantly more with FCM treatment than
with oral iron. In addition, iron repletion was significantly
faster with FCM than with oral iron; the difference could
be clearly identified by 2 weeks after the first dose of
FCM.
In contrast, administration of large doses of other IV iron
agentshasbeenassociatedwithhighratesofadverseevents.
Iron dextran can be administered as high-dose infusion but
may be associated with life-threatening anaphylaxis or
death [18,19,26–28]. Although second-generation paren-
teralironproductsaremuchlesslikelytocauseanaphylactic
reactions,dosesof ironsucrose>300mgperinfusionorfer-
ric gluconate >250 mg are not recommended, as they have
been associated with higher rates of adverse reactions such
as hypotension [2,14,16,29–33]. In a study of iron sucrose,
adverse events occurred in 36% of subjects who received
500-mg doses [29]. Another study reported that an infusion
of 500 mg of iron sucrose over 3.5–4 h was associated with
hypotension in 6.7% of subjects [14]. Similarly, administra-
tion of 500 mg of sodium ferric gluconate over 5 h resulted
in a 30% rate of adverse events including hypotension [30].
Thus, safe administration of a typical 1000-mg course of IV
iron sucrose or ferric gluconate will require either long in-
fusion times [14,30] or from five to eight clinic visits with
repeated venipuncture. This is clearly inconvenient for out-
patient administration and adds to the expense for both pa-
tients and healthcare providers. In contrast, 1000 mg of
FCM can be administered in a single dose in only 15 min,
which would require fewer clinic visits and venipunctures.
Thus, FCM appears to be better suited for outpatient use in
ND-CKD patients. Only one other IV iron preparation, fer-
umoxytol, which can be quickly administered in 500-mg
doses, has been shown to be superior to oral iron, but it still
requirestwoseparateclinicvisitsfora1000-mgcourse[25].
Besides its efficacy, FCM administration was well toler-
ated and was associated with fewer adverse events than oral
iron. No adverse event that was considered drug-related
occurred in more than one FCM-treated subject, and no
anaphylactoid reactions were reported. In subjects receiv-
ing oral iron, however, adverse events included constipa-
tion, discoloured faeces, upper abdominal pain, diarrhoea
and nausea. Thus, while oral iron is a convenient and less
expensive option of treating iron deficiency in patients
with CKD, its efficacy in replenishing iron stores may be
limited by its ineffective absorption, potential for gastro-
intestinal adverse events and non-compliance [14,15,22].
Transient hypophosphataemia that was observed in four
subjects (2.7%) in the FCM group was not associated with
any clinically relevant adverse event and was much less
frequent than previously reported in women with heavy
uterine bleeding who received IV FCM therapy [22].
The cause of hypophosphataemia in these subjects is not
clear, but this adverse effect has been previously reported
in other haematopoietic disorders [34–36]. The decrease in
serum phosphorus in these clinical conditions suggests in-
creased cellular uptake of phosphorus during stimulated
erythropoiesis[37,38].However,renal tubular leak ofphos-
phorus cannot be excluded. A recent study by Schouten et
al. implicated increased FGF-23 levels in the development
of hypophosphataemia after parenteral iron administration
[39]. There is an obvious need for further evaluation of this
issue in FCM-treated patients in order to ascertain its mech-
anism and clinical consequences, if any.
Among the multiple developmental clinical trials with
FCM in various clinical conditions, including CKD, there
was a numerical imbalance in deaths (5/1206 with FCM
and 1/994 with iron sucrose in controlled trials, and 5/
925 with FCM in uncontrolled trials) including the two
deaths in the subjects who were part of the current study.
None of these two deaths was determined by the investiga-
tor to be related to the study medication. Although the
FDA issued a non-approval letter, pending further studies
to assess the safety of FCM, the drug has been registered
by the public health authorities in Europe since 2007 and
has been used to treat iron deficiency anaemia in over 20
countries. Current studies are underway in the USA to
evaluate more rigorously this issue [40].
There are a number of limitations to our study. First, the
duration of the study was relatively short; this does not
allow conclusions about long-term efficacy and safety of
FCM compared with oral iron. Second, the relative cost
of FCM compared with oral iron and other IV iron pre-
parations is not currently available. These comparisons
will have to be inclusive of the cost of supplies such as
infusion sets, nursing time and, most importantly, patient
convenience.
In conclusion, IV administration of FCM was more
effective than oral iron for increasing Hb level and replen-
ishing iron stores in ND-CKD patients with iron deficiency
anaemia and was associated with fewer adverse events. Im-
portantly,becauseitcanbegiveninlargesingledoses,ferric
carboxymaltose is more convenient than oral iron therapy
for outpatient administration in ND-CKD patients.
Supplementary data
Supplementary data is available online at http://ndt.
oxfordjournals.org.
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